AKT1 and cancer: The Cancer Genome Atlas data demonstrated that the most frequently altered genomic drivers in TNBC include the phosphatidylinositol 3-kinase-AKT-mTOR (PI3K-AKT-mTOR) signaling pathway.10,11 The mTOR inhibitor everolimus in combination with eribulin or carboplatin has shown moderate activity.12,13 Ipatasertib is a selective ATP–competitive small–molecule inhibitor of AKT that preferentially targets active phosphorylated Akt (pAkt) and is potent in cell lines with evidence of Akt activation.